Table 1 Pretreatment pathoclinical characteristics of the 599 patients eligible for this study
Characteristic | Value |
|---|---|
Age at diagnosis (years old) | 56 (18–75) |
No. of patients by gender | |
Male | 396 (66.1%) |
Female | 203 (33.9%) |
No. of patients by tumor differentiation | |
Low | 63 (10.5%) |
Moderate | 458 (76.5%) |
High | 78 (13.0%) |
Distance to anal verge (cm) | 5.0 (1.0–15.0) |
No. of patients by clinical T stage | |
cT4b | 26 (4.3%) |
cT4a | 249 (41.6%) |
cT3 | 314 (52.4%) |
cT2 | 10 (1.7%) |
cT1 | 0 (0.0%) |
No. of patients by clinical N stage | |
cN2 | 213 (35.6%) |
cN1 | 280 (46.7%) |
cN0 | 106 (17.7%) |
CEA (ng/ml) | 4.2 (0.0-392.0) |
CA19-9 (U/ml) | 13.8 (0.0-985.6) |
ApoAI (g/L) | 1.19 (0.51–2.05) |
ApoB (g/L) | 0.90 (0.39–1.78) |
ApoB-to-apoAI ratio | 0.75 (0.23–1.92) |
No. of patients by radiotherapy technique | |
3DCRT | 163 (27.2%) |
IMRT | 436 (72.8%) |
No. of patients by TRG | |
5 | 16 (2.7%) |
4 | 107 (17.8%) |
3 | 202 (33.7%) |
2 | 137 (22.9%) |
1 | 137 (22.9%) |
No. of patients by pathological T stage | |
pT4b | 13 (2.2%) |
pT4a | 36 (6.0%) |
pT3 | 240 (40.1%) |
pT2 | 135 (22.5%) |
pT1 | 24 (4.0%) |
pT0 | 151 (25.2%) |
No. of patients by pathologic N stage | |
pN2 | 26 (4.3%) |
pN1 | 103 (17.2%) |
pN0 | 470 (78.5%) |
Chemotherapy cycle | 7 (4–10) |
No. of patients by active viral hepatitis | |
Yes | 82 (13.7%) |
No | 517 (86.3%) |